Pfaltz C R, Aoyagi M
ORL Department, University Hospital, Basle, Switzerland.
Acta Otolaryngol Suppl. 1988;460:135-42. doi: 10.3109/00016488809125147.
Based upon the results of a double-blind study carried out in a series of 120 patients suffering from vertigo and objective vestibular symptoms, we made the following observations during the treatment of vestibular disorders by means of calcium-entry blockers: Subjective symptoms regress fairly well during treatment, but no better than after betahistine-dihydrochloride (BHC) or thietylperazine therapy (TP). Objective assessment of the therapeutic action of calcium antagonists on vestibular dysfunction is based on the results of the Harmonic Acceleration test, which was carried out by using a computerized rotatory chair. The most reliable parameter with respect to the objective assessment of the experimentally induced vestibular responses (VOR) is the gain. Our test results show a progressive decrease in GAIN, indicating a depressive or inhibitory effect of the calcium antagonist flunarizine upon the VOR. If we compare these results with those obtained in the betahistidine- and thiethylperazine groups, we cannot confirm the same decline in GAIN within the latter two groups. A statistical analysis demonstrates a significant difference between the F-gain on the one hand, and the BHC gain and TP gain on the other hand.
基于对120例患有眩晕和客观性前庭症状患者进行的双盲研究结果，我们在使用钙通道阻滞剂治疗前庭疾病的过程中得出以下观察结果：治疗期间主观症状消退情况相当良好，但并不比使用二盐酸倍他司汀（BHC）或硫乙拉嗪疗法（TP）后更好。钙拮抗剂对前庭功能障碍治疗作用的客观评估基于谐波加速度测试结果，该测试使用计算机化转椅进行。关于对实验诱导的前庭反应（VOR）进行客观评估，最可靠的参数是增益。我们的测试结果显示增益逐渐下降，表明钙拮抗剂氟桂利嗪对VOR有抑制作用。如果将这些结果与在倍他司汀组和硫乙拉嗪组中获得的结果进行比较，我们无法证实在后两组中增益有同样程度的下降。统计分析表明，一方面F增益与另一方面BHC增益和TP增益之间存在显著差异。
